Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-PSMA in Recurrent/Metastatic Adenoid Cystic Carcinoma
NCT06199453Phase 2Withdrawn
- Sponsor
- Maria Skłodowska-Curie National Research Institute of Oncology
- Start
- Jan 2024
- Primary completion
- Nov 2027
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 2 trial of lutetium lu 177 vipivotide tetraxetan in adenoid cystic carcinoma (ACC), sponsored by Maria Skłodowska-Curie National Research Institute of Oncology. Planned start Jan 2024; status: withdrawn.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
adenoid cystic carcinoma (ACC)
Beyond the preview
Go deeper on NCT06199453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06199453.